Reply to comments: duration of antimicrobial therapy for Gram-negative bacteremia secondary to urinary source of infection
We sincerely thank Dr. Karakonstantis and colleagues for their interest in our study regarding the duration of antimicrobial therapy for Gram-negative bacteremia . We appreciate the insightful comments and suggestion to conduct a subgroup analysis in patients with a urinary source of bacteremia .
Patients with bacteremia complicating urinary tract infections (UTI) have a considerable risk of 28-day mortality, estimated at 5% in population-based settings, likely due to high acute severity of illness . Long-term complications, including those due to hematogenous dissemination of the bacteria, likely contribute to the 16% mortality within 1 year of bacteremia . Optimization of empirical and definitive antimicrobial therapy is essential to improve short- and long-term outcomes of patients with Gram-negative bacteremia, respectively.
A subgroup analysis was conducted in 282 patients with a urinary source of Gram-negative bacteremia, including 81 who received short...
ANN received funding from the Medical Scholars Program 2016 of the Infectious Disease Society of America Education and Research Foundation. Funding source had no role in study design. The study had no other sources of funding.
Compliance with ethical standards
Conflicts of interest
MNA and PBB: Continuing medical education steering committee for Rockpointe Corporation, Columbia, MD, USA. ANN, HA, JK and JAJ: No conflicts.
- 4.Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–20.CrossRefPubMedGoogle Scholar
- 5.van Nieuwkoop C, van der Starre WE, Stalenhoef JE, van Aartrijk AM, van der Reijden TJ, Vollaard AM, et al. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double blind, placebo-controlled non-inferiority trial in men and women. BMC Med. 2017;15:70.CrossRefPubMedPubMedCentralGoogle Scholar